Current Management of Primary CNS Lymphoma

Core Treatment Principles

The European Society for Medical Oncology recommends that the chemotherapeutic regimen for primary CNS lymphoma should contain high-dose methotrexate combined with high-dose cytarabine and rituximab, as this combination improves complete remission rates and outcomes, typically followed by consolidation with CNS irradiation 1, 2, 3, 4
Primary CNS lymphoma represents a distinct clinical entity requiring fundamentally different treatment than systemic DLBCL, with anthracycline-based regimens like R-CHOP being inappropriate due to poor blood-brain barrier penetration 1, 2

Standard Induction Regimen Components

High-dose methotrexate is the mandatory foundation of any primary CNS lymphoma regimen, as recommended by the European Society for Medical Oncology 1, 2, 3, 4, 5, 6, 7
The addition of high-dose cytarabine significantly improves complete remission rates and overall outcomes, according to the European Society for Medical Oncology 1, 2, 3, 4

Consolidation Strategy

CNS irradiation is typically administered as consolidation after achieving response with induction chemotherapy, as recommended by the European Society for Medical Oncology 1, 2, 3, 4

Critical Treatment Considerations

Tumor lysis syndrome prophylaxis is essential, given the potential high tumor burden in CNS lymphoma, as recommended by the European Society for Medical Oncology 1, 7
Growth factor support should be considered to maintain dose intensity, according to the European Society for Medical Oncology 1, 7
Avoiding dose reductions is critical for optimal outcomes, as recommended by the European Society for Medical Oncology 1, 5, 7

Response Assessment

Repeat imaging after 3-4 cycles and after completion of treatment is recommended, according to the European Society for Medical Oncology 1, 3, 4
PET scanning should be incorporated into response evaluation when positive at baseline, as recommended by the European Society for Medical Oncology 1, 3, 4

Common Pitfalls to Avoid

Omitting high-dose cytarabine is not recommended, as it significantly improves complete remission rates and outcomes, according to the European Society for Medical Oncology 1, 2, 3, 4

Hematopoietic Growth Factors for Primary CNS Lymphoma

Growth Factor Support

Growth factor support with G-CSF (filgrastim) or pegfilgrastim should be strongly considered for patients receiving high-dose methotrexate and high-dose cytarabine regimens for primary CNS lymphoma to maintain dose intensity and prevent febrile neutropenia 8

Dosing and Administration

Filgrastim should be administered at 5 µg/kg/day subcutaneously starting 24-72 hours after the last day of chemotherapy until adequate neutrophil recovery (ANC >1.0 × 10⁹/L) 9, 10
Pegfilgrastim should be administered as a single subcutaneous dose of 6 mg (or 100 µg/kg if individualized) given 24-72 hours after chemotherapy completion 8, 10

Critical Contraindications

G-CSF should never be administered during concurrent chest radiotherapy due to increased complications and mortality risk 9, 10
Growth factors should be avoided immediately before or simultaneously with chemotherapy due to severe thrombocytopenia risk 9

High-Dose Cytarabine Toxicities

The National Comprehensive Cancer Network recommends performing neurological examination before each cytarabine dose, focusing on cerebellar function, as cerebellar toxicity is a significant risk 11

Laboratory Monitoring Protocol

The National Comprehensive Cancer Network recommends mandatory baseline labs, including complete blood count with differential, comprehensive metabolic panel, hepatitis screening, cardiac assessment, lactate dehydrogenase, and HIV testing 12, 13, 14, 15
Hepatitis B surface antigen and core antibody screening is mandatory before rituximab, with monitoring of HBV DNA every 1-3 months during and for 6-12 months after rituximab 12, 13, 14

Special Monitoring Considerations

Tumor lysis syndrome prophylaxis is mandatory given high tumor burden in CNS lymphoma, with monitoring of potassium, phosphate, calcium, uric acid, and LDH daily for the first 3-5 days 12
If using G-CSF, complete blood count should be checked twice weekly during administration, with discontinuation when ANC recovers to >1.0 × 10⁹/L 8, 9, 10

First‑Line Management of Primary Central Nervous System Diffuse Large B‑Cell Lymphoma

Induction Regimen

High‑dose methotrexate (≥ 3 g/m² administered as a 3‑hour infusion) is the cornerstone of all first‑line protocols for primary CNS DLBCL, providing the necessary CNS penetration 16.
Recommended induction combinations, validated in prospective trials, include:
- MATRix (methotrexate + cytarabine + thiotepa + rituximab)
- ReMBVP (methotrexate + carmustine + vincristine + procarbazine)
- ReMPV (methotrexate + procarbazine + vincristine) 16.
Adding high‑dose cytarabine to the methotrexate backbone significantly increases complete‑remission rates and improves clinical outcomes (evidence from prospective series) 16.
The incremental benefit of rituximab in methotrexate‑based poly‑chemotherapy remains uncertain and the combination is not approved by EMA or FDA for this indication 16.

Consolidation Strategy

Fit (younger) patients or those with good functional status

Autologous stem‑cell transplantation with high‑dose conditioning (HDC‑ASCT) is recommended as consolidation for patients who achieve responsive or stable disease after induction 16.
Conditioning regimens should be thiotepa‑based, combined with busulfan or carmustine according to established protocols 16.
Eligibility for HDC‑ASCT must be reassessed dynamically during treatment, especially in older individuals 16.

Patients not eligible for transplant

Reduced‑dose whole‑brain radiotherapy (36–40 Gy in 20 fractions) is advised for younger patients who cannot undergo transplant 16.
In elderly patients, full‑dose radiotherapy should be avoided or deferred because of a high risk of disabling neurocognitive decline 16.
A lower radiotherapy dose (≈ 23 Gy) may be used for patients with responsive disease, although long‑term cognitive effects are not fully defined 16.
For elderly patients in complete remission after induction, a watch‑and‑wait approach can be considered 16.

Supportive Care & Dose Adjustments

Methotrexate dosing should be judiciously reduced according to renal function and comorbidities to prevent toxicity 16.

Response Assessment

Repeat neuro‑imaging (MRI) after 3–4 induction cycles and at the end of therapy to evaluate disease status 16.
Incorporate FDG‑PET when baseline scans are PET‑positive; early PET (after 1–4 cycles) may have prognostic value but should not trigger treatment changes outside clinical trials 16.

Intrathecal Chemotherapy

Routine intrathecal chemotherapy is not recommended; it is reserved only for patients with cerebrospinal‑fluid dissemination who cannot receive high‑dose methotrexate or who have persistent meningeal disease at the end of first‑line therapy 16.

Management of Patients Ineligible for High‑Dose Methotrexate

Approximately 15 % of patients are unsuitable for high‑dose methotrexate because of advanced age, frailty, or comorbidities; shared decision‑making about life expectancy, functional goals, and quality of life is essential 16.
For selected frail patients where symptomatic benefit is unlikely, best‑supportive‑care measures are preferred 16.
Palliative options include oral alkylating agents (e.g., temozolomide, carmustine, procarbazine) with or without rituximab, and focal radiotherapy (30–36 Gy in 10–15 fractions) 16.

Common Pitfalls to Avoid

Do not use anthracycline‑based regimens such as R‑CHOP for primary CNS DLBCL, as they lack adequate blood‑brain‑barrier penetration 16.
Do not omit high‑dose cytarabine when feasible, given its proven impact on complete‑remission rates 16.
Do not deliver full‑dose consolidative radiotherapy to elderly patients because of prohibitive neurocognitive toxicity 16.

Clinical‑Trial Participation

Enrollment in appropriate prospective clinical trials should be offered to every patient with primary CNS DLBCL 16.

Consolidation Strategies for Primary CNS Lymphoma with Residual Disease after MTR Induction

1. Induction Regimen Context

2. Response Assessment and Decision‑Making

3. Preferred Consolidation: High‑Dose Chemotherapy with Autologous Stem‑Cell Transplant (HDC‑ASCT)

4. Alternative Consolidation: Reduced‑Dose Whole‑Brain Radiotherapy (WBRT)

5. Intensification Before Consolidation (Optional)

6. Key Management Recommendations

Consolidation Therapy for Primary CNS Lymphoma: High‑Dose Chemotherapy with Autologous Stem‑Cell Transplantation

Patient Selection for HDC‑ASCT

Fit adults (generally ≤ 65–70 years) with responsive or stable disease after high‑dose methotrexate‑based induction should receive high‑dose chemotherapy with autologous stem‑cell transplantation (HDC‑ASCT) 25.
Biological fitness, not chronological age alone, determines eligibility; fitness must be reassessed throughout induction because older patients may gain or lose transplant suitability 25.

Conditioning Regimens

Thiotepa‑based conditioning is mandatory for HDC‑ASCT, showing superior efficacy to BEAM regimens used in systemic lymphoma [26][25]27.
Thiotepa should be combined with either busulfan or carmustine according to established protocols 25.
Dose adjustments are required based on individual fitness and comorbidities 25.

Efficacy of Thiotepa‑Based HDC‑ASCT

The IELSG‑32 trial (randomized phase II) reported a 7‑year overall survival (OS) of 70 % for patients receiving MATRix induction followed by HDC‑ASCT 28.
The MATRix/IELSG‑43 trial (prospective phase II) demonstrated 3‑year progression‑free survival (PFS) of 79 % and 3‑year OS of 86 % with thiotepa‑based ASCT [29][30].

Rationale for HDC‑ASCT

High‑dose, blood‑brain‑barrier‑penetrating cytostatics delivered by HDC‑ASCT overcome drug resistance and achieve therapeutic CNS concentrations [26][27].
This approach eradicates residual disease and reduces relapse risk more effectively than alternative consolidation strategies [26][27].

Alternative Consolidation: Whole‑Brain Radiotherapy (WBRT)

Indications

WBRT is a valid alternative for fit patients who cannot harvest sufficient autologous stem cells, who decline HDC‑ASCT, or who have residual disease after HDC‑ASCT [26][27].
Reduced‑dose WBRT (23.4 Gy) may be used for patients with responsive disease after induction chemotherapy 25.

Dose Strategies

Conventional WBRT (36–40 Gy in 20 fractions) is recommended for younger patients unsuitable for ASCT 25.
Reduced‑dose WBRT (23.4 Gy in 13 fractions) has shown encouraging outcomes in prospective studies [29][30]; dose should be tailored to post‑induction response [26][27].

Efficacy & Safety

The RTOG 1114 randomized trial reported median PFS not reached at 55 months with reduced‑dose WBRT + chemotherapy versus 25 months with chemotherapy alone [26][27].
Whole‑brain irradiation is mandatory because focal radiotherapy leads to higher relapse rates outside the treated volume [26][27].
Approximately 40 % of primary CNS lymphoma (PCNSL) cases are multifocal; conventional MRI underestimates disease extent [26][27].
Stereotactic radiotherapy, radiosurgery, and hippocampal‑sparing techniques should be confined to clinical trials due to limited prospective evidence [26][27].
Long‑term cognitive toxicity of WBRT, especially in elderly patients, drives preference for HDC‑ASCT [26][27]; cognitive effects of reduced‑dose WBRT remain incompletely defined in older adults 25.

Non‑Myeloablative Chemotherapy (Experimental)

Non‑myeloablative regimens are experimental and should be limited to clinical trials [26][29]30.
The ALLIANCE 51101 study (randomized phase II) showed inferior 2‑year PFS for non‑myeloablative high‑dose cytarabine‑etoposide (51 %) versus HDC‑ASCT (73 %) (p = 0.02) [26][29]30.
The MATRix/IELSG‑43 trial demonstrated that the ReDeVIC regimen was significantly inferior to thiotepa‑based ASCT (3‑year PFS 53 % vs 79 %; 3‑year OS 71 % vs 86 %) [29][30].

Management of Patients Unsuitable for HDC‑ASCT (Elderly or Frail)

Conventional WBRT (36–40 Gy) should be avoided or deferred in patients > 65–70 years because of a high risk of disabling neurocognitive impairment [25][30].
Reduced‑dose WBRT (23.4 Gy) in first complete remission offers encouraging survival without clear evidence of significant cognitive decline, though data in the elderly are limited [29][30].
Watchful waiting may be considered for elderly patients in complete remission after standard induction immunochemotherapy [25][30].
Only 2–8 % of elderly patients receive WBRT consolidation, reflecting a shift toward neurotoxicity avoidance [29][30].
Maintenance with oral alkylating agents (e.g., procarbazine) or immunomodulators (e.g., lenalidomide) can be individualized for frail patients 25.

Timing and Response Assessment

Consolidation therapy should commence promptly after documented response to eliminate residual disease and lower relapse risk [26][27].
Relapses are common when consolidation is omitted despite high initial response rates to high‑dose methotrexate [26][27].
Disease response must be evaluated using International PCNSL Collaborative Group criteria 25; repeat MRI after 3–4 induction cycles and at induction completion is recommended 25.
Autologous stem‑cell collection should occur after induction and before consolidation; insufficient harvest mandates WBRT instead [25][26]27.

Common Pitfalls to Avoid

Do not use conventional‑dose WBRT (> 40 Gy) in patients around 60 years or older because of prohibitive neurocognitive toxicity [25][30].
Do not employ non‑myeloablative chemotherapy outside of clinical trials, given its inferiority to thiotepa‑based ASCT [26][29]30.
Do not omit consolidation in fit patients; lack of consolidation markedly increases relapse risk [26][27].

Special Populations

Patients with partial response or stable disease after induction are eligible for consolidation (HDC‑ASCT or WBRT) 25.
Progressive disease after induction signifies treatment failure and requires salvage therapy (e.g., high‑dose cytarabine or ifosfamide‑based regimens) rather than consolidation [31][32].